· 自动抓取 · 最新研究  · 1 分钟阅读

Leukemic architecture as a framework for risk stratification in NPM1-mutated acute myeloid leukemia.

NPM1-mutated (NPM1c) acute myeloid leukemia (AML) has traditionally been considered a genetically defined entity associated with a favorable prognosis. However, growing evidence indicates that NPM1c A

NPM1-mutated (NPM1c) acute myeloid leukemia (AML) has traditionally been considered a genetically defined entity associated with a favorable prognosis. However, growing evidence indicates that NPM1c A

NPM1-mutated (NPM1c) acute myeloid leukemia (AML) has traditionally been considered a genetically defined entity associated with a favorable prognosis. However, growing evidence indicates that NPM1c AML comprises biologically and clinically heterogeneous disease states, in which NPM1c acts less as an autonomous prognostic determinant and more as a context-dependent organizer of leukemic architecture. Integrative transcriptomic and epigenomic studies have identified reproducible stemness-linked p


本文自动抓取自 PubMed,原文链接:Leukemic architecture as a framework for risk stratification in NPM1-mutated acute myeloid leukemia.

原文发布日期:2026-07-08

Related Posts

View All Posts »
异基因造血细胞移植后复发患者接受供者淋巴细胞输注的时机:单中心回顾性分析

异基因造血细胞移植后复发患者接受供者淋巴细胞输注的时机:单中心回顾性分析

供者淋巴细胞输注(DLI)是应对异基因造血干细胞移植(allo-HCT)后复发的重要策略。本研究回顾分析了2010至2022年间,83名在移植后复发并接受DLI的急性白血病或骨髓增生异常综合征(MDS)成年患者。通过每月检测嵌合度和基因标志物,将治疗分为“抢先治疗”(在分子复发时进行)和“常规治疗”(在明显的血液学复发时进行)。 生存分析表明,常规治疗组的生存率显著劣于抢先治疗组,其中常规治疗组